TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial
Press Releases
TransCode Therapeutics, Inc.  
March 13, 2025

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

Clinical trial Safety Review Committee (SRC) approved opening of Cohort 4 based on favorable safety data from the three patients comprising Cohort 3No significant safety or dose limiting toxicities reported

avatar profile Olean Times Herald

Olean Times Herald


Local & Social